{"id":2176,"date":"2026-10-05T07:57:40","date_gmt":"2026-10-05T02:27:40","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-10-05\/"},"modified":"2026-10-05T20:21:14","modified_gmt":"2026-10-05T14:51:14","slug":"auropharma-share-price-today-2026-10-05","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-10-05\/","title":{"rendered":"Why Aurobindo Pharma Shares Slipped 0.11% Today Amid Sector Weakness | 5 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div data-approved-layout=\"1061-v1\" class=\"wt-article-v4\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: AUROPHARMA<\/strong> \u00b7 5 October 2026 \u00b7 Dated market coverage<\/p>\n<div style=\"flex-wrap:wrap;gap:7px;margin:8px 0 14px;\" class=\"wt-price-strip\">\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Price<\/div>\n<div style=\"font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">\u20b91,674.90<\/div>\n<\/p><\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Change<\/div>\n<div style=\"font-weight:900;color:#b42318;margin-top:2px;overflow-wrap:anywhere;\">-0.11%<\/div>\n<\/p><\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">High \/ Low<\/div>\n<div style=\"font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">\u20b91,696.00 \/ \u20b91,663.10<\/div>\n<\/p><\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Prev. Close<\/div>\n<div style=\"font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">\u20b91,676.80<\/div>\n<\/p><\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Volume<\/div>\n<div style=\"font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">9.26L<\/div>\n<\/p><\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Updated<\/div>\n<div style=\"font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">03:15 PM<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<div style=\"background:#f7fbff;border:1px solid #cfe1f2;border-left:4px solid #2e7db2;border-radius:10px;padding:13px 15px;margin:12px 0 18px;\" class=\"wt-card\">\n<div style=\"font-weight:900;color:#1f4d70;margin-bottom:6px;\" class=\"wt-card-title\">Key Takeaways<\/div>\n<ul style=\"margin:0;padding-left:18px;\">\n<li>AUROBINDO PHARMA LTD was trading<strong>0.11% lower<\/strong>at \u20b91,674.90 and around the middle of the day&#8217;s trading range. <\/li>\n<li><strong>Likely reason:<\/strong>Sector-linked consolidation and low-volume drift. <\/li>\n<li>Cash volume was around<strong>1.19x the recent 20-day average<\/strong>, indicating above-normal participation. <\/li>\n<\/ul><\/div>\n<h2>Why Aurobindo Pharma Shares Are Falling 0.11% Today<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Aurobindo Pharma shares remained relatively flat during Monday&#8217;s session, edging down 0.11% to close at \u20b91,674.90. The stock opened higher at \u20b91,688.10 and oscillated within a day&#8217;s range of \u20b91,663.10 and \u20b91,696.00. Trading volumes were close to recent averages, with total volume standing at around 9.25 lakh shares, indicating subdued participation relative to its 20-day moving average.<\/p>\n<p class=\"wt-copy\">While the broader Nifty index finished positive with a 0.60% gain, Aurobindo Pharma underperformed alongside the broader Nifty Pharma sector, which slipped 0.74% for the day. The stock&#8217;s modest pullback aligns with the sector-wide weakness rather than any standalone negative catalysts, reflecting cautious sentiment in pharmaceutical names during the session.<\/p>\n<p class=\"wt-copy\">The stock continues to digest a series of positive operational updates from recent weeks, including USFDA final approvals for Perampanel Tablets and Beclomethasone Dipropionate HFA Inhalation Aerosol, alongside the launch of ADQUEY in the U.S. through Acrotech Biopharma. While these announcements reinforce execution visibility in complex generics and specialty portfolios, they served as background context rather than immediate intraday catalysts for today&#8217;s range-bound price action.<\/p>\n<\/div>\n<div style=\"border:1px solid #c9d9e7;border-left:5px solid #1f7b92;border-radius:10px;background:#f5fbfd;padding:14px 16px;margin:15px 0 20px;\" class=\"wt-card\">\n<div style=\"font-weight:900;color:#174c5d;margin-bottom:6px;\" class=\"wt-card-title\">Likely Reason for Today&#8217;s Move<\/div>\n<div style=\"font-weight:850;color:#20384a;margin-bottom:6px;\">Sector-linked consolidation and low-volume drift<\/div>\n<div style=\"\">The minor negative change of 0.11% occurred alongside a broader sectoral decline in the Nifty Pharma index, with trading volumes staying near normal levels and no active single-day catalyst driving immediate price action.<\/div>\n<ul style=\"margin:8px 0 0;padding-left:18px;\">\n<li>Nifty Pharma sector declined by 0.74%<\/li>\n<li>Trading volume was close to the 5-day average volume ratio of 0.93<\/li>\n<li>Absence of fresh same-day news announcements<\/li>\n<\/ul><\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div style=\"gap:10px;margin:10px 0 22px;\" class=\"wt-card\">\n<div style=\"border:1px solid #dce5eb;border-radius:10px;padding:13px 14px;background:#fff;min-width:0;\">\n<div style=\"font-weight:900;color:#17324d;\">USFDA Final Approval for Perampanel Tablets<\/div>\n<div style=\"color:#708090;margin:3px 0 6px;\">03-Oct-2026<\/div>\n<div style=\"color:#34495d;\">Aurobindo Pharma announced that it received final approval from the United States Food and Drug Administration (USFDA) for Perampanel Tablets in strengths ranging from 2 mg to 12 mg. Perampanel is a central nervous system medication used in the management of seizures. This regulatory clearance adds another complex generic product to the company&#8217;s expanding U.S. portfolio.<\/div>\n<\/p><\/div>\n<div style=\"border:1px solid #dce5eb;border-radius:10px;padding:13px 14px;background:#fff;min-width:0;\">\n<div style=\"font-weight:900;color:#17324d;\">Acrotech Biopharma Launches ADQUEY in the U.S.<\/div>\n<div style=\"color:#708090;margin:3px 0 6px;\">30-Sep-2026<\/div>\n<div style=\"color:#34495d;\">The company&#8217;s subsidiary, Acrotech Biopharma, successfully launched ADQUEY in the United States and formally established a dedicated dermatology business segment. The rollout marks a strategic expansion into the specialized U.S. dermatology market, broadening the group&#8217;s commercial footprint beyond traditional generics.<\/div>\n<\/p><\/div>\n<div style=\"border:1px solid #dce5eb;border-radius:10px;padding:13px 14px;background:#fff;min-width:0;\">\n<div style=\"font-weight:900;color:#17324d;\">USFDA Final Approval for Beclomethasone Inhalation Aerosol<\/div>\n<div style=\"color:#708090;margin:3px 0 6px;\">15-Sep-2026<\/div>\n<div style=\"color:#34495d;\">Aurobindo Pharma received final USFDA approval for Beclomethasone Dipropionate HFA Inhalation Aerosol in 40 mcg and 80 mcg strengths. The respiratory product addresses complex inhalation requirements, reflecting the company&#8217;s ongoing shift toward difficult-to-make generic formulations.<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div style=\"gap:12px;margin:11px 0 22px;\">\n<div style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:5px solid #cc922c;border-radius:10px;padding:14px 15px;min-width:0;\" class=\"wt-card\">\n<div style=\"font-weight:900;color:#8c6318;margin-bottom:9px;\" class=\"wt-card-title\">Promoter Pledge \/ Encumbrance<\/div>\n<div style=\"gap:7px;\">\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"text-transform:uppercase;color:#74808d;font-weight:800;\">Promoter Holding<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:3px;\">51.88%<\/div>\n<div style=\"color:#71808d;margin-top:2px;\">51.82% previous qtr<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<div style=\"background:#f5f8fb;border:1px solid #d5e0ea;border-left:5px solid #6a849c;border-radius:10px;padding:14px 15px;min-width:0;\" class=\"wt-card\">\n<div style=\"font-weight:900;color:#405d76;margin-bottom:9px;\" class=\"wt-card-title\">Recent Ownership \/ Shareholding<\/div>\n<div style=\"gap:7px;\">\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"text-transform:uppercase;color:#74808d;font-weight:800;\">FII\/FPI<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:3px;\">16.38%<\/div>\n<div style=\"color:#71808d;margin-top:2px;\">15.24% previous qtr<\/div>\n<\/p><\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"text-transform:uppercase;color:#74808d;font-weight:800;\">Mutual Funds<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:3px;\">16.71%<\/div>\n<div style=\"color:#71808d;margin-top:2px;\">17.79% previous qtr<\/div>\n<\/p><\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"text-transform:uppercase;color:#74808d;font-weight:800;\">Institutional<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:3px;\">41.48%<\/div>\n<div style=\"color:#71808d;margin-top:2px;\">41.11% previous qtr<\/div>\n<\/p><\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"text-transform:uppercase;color:#74808d;font-weight:800;\">MF Schemes<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:3px;\">42<\/div>\n<div style=\"color:#71808d;margin-top:2px;\">41 previous qtr<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div style=\"border:1px solid #d5e0ea;border-radius:11px;background:#f7f9fc;padding:14px 15px;margin:10px 0 22px;\" class=\"wt-card\">\n<div style=\"color:#34495d;margin-bottom:10px;\">Mutual funds decreased their aggregate stake to<strong>16.71%<\/strong>from <strong>17.79%<\/strong>in the previous quarter. The number of disclosed MF\/UTI shareholders was 42, versus 41 in the previous quarter. <\/div>\n<div style=\"gap:8px;\">\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:9px;padding:10px 11px;min-width:0;\">\n<div style=\"font-weight:850;color:#20384a;\">QUANT MUTUAL FUND<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:4px;\">28.55M shares \u2022 4.96%<\/div>\n<div style=\"color:#74808d;margin-top:2px;\">30-JUN-2026<\/div>\n<\/p><\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:9px;padding:10px 11px;min-width:0;\">\n<div style=\"font-weight:850;color:#20384a;\">SBI LARGE &amp; MIDCAP FUND<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:4px;\">20.53M shares \u2022 3.57%<\/div>\n<div style=\"color:#74808d;margin-top:2px;\">30-JUN-2026<\/div>\n<\/p><\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:9px;padding:10px 11px;min-width:0;\">\n<div style=\"font-weight:850;color:#20384a;\">HDFC MUTUAL FUND<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:4px;\">18.53M shares \u2022 3.22%<\/div>\n<div style=\"color:#74808d;margin-top:2px;\">30-JUN-2026<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<h2>Research &amp; Brokerage Views<\/h2>\n<div style=\"border:1px solid #cbd8ea;border-radius:11px;background:#f4f8fd;padding:13px 14px;margin:10px 0 22px;\" class=\"wt-card\">\n<div style=\"gap:8px;\">\n<div style=\"background:#fff;border:1px solid #dfe7f0;border-radius:9px;padding:10px 11px;min-width:0;\">\n<div style=\"font-weight:900;color:#21384f;\">Nuvama<\/div>\n<div style=\"margin-top:4px;\"><strong>Buy<\/strong><\/div>\n<div style=\"color:#74808d;margin-top:2px;\">23 Jun 2026<\/div>\n<div style=\"color:#536273;margin-top:5px;\">Maintained a Buy rating following solid delivery across core generic markets and strategic specialty pipeline progress.<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<div style=\"color:#6d7885;margin-top:8px;\">Third-party brokerage opinions; not WittyTrades recommendations.<\/div>\n<\/p><\/div>\n<h2>What to Watch Next<\/h2>\n<ul style=\"\">\n<li>Execution progress and revenue contribution from the newly launched ADQUEY dermatology line in the U.S.<\/li>\n<li>Commercialization timelines for recent USFDA approvals including Perampanel and Beclomethasone inhalation aerosols<\/li>\n<li>Updates on ongoing USFDA regulatory inspections across Apitoria Pharma subsidiary manufacturing units<\/li>\n<\/ul>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<h3 style=\"margin:13px 0 4px;\">Why is AUROBINDO PHARMA LTD share price falling today?<\/h3>\n<p style=\"margin:0;\" class=\"wt-copy\">The minor negative change of 0.11% occurred alongside a broader sectoral decline in the Nifty Pharma index, with trading volumes staying near normal levels and no active single-day catalyst driving immediate price action.<\/p>\n<h3 style=\"margin:13px 0 4px;\">How strong is trading participation today?<\/h3>\n<p style=\"margin:0;\" class=\"wt-copy\">Participation is above normal. Volume is about 1.19x the latest 20-day average.<\/p>\n<div style=\"color:#606b78;border-top:1px solid #e1e7ef;padding-top:13px;margin-top:22px;\"><strong>Disclaimer:<\/strong>Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is informational and educational, not personalised investment advice or a recommendation. Market data may be delayed; verify current information before acting. <\/div>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-10-01\/\">Aurobindo Pharma in Focus After U.S. ADQUEY Launch; What to Watch Today \u2014 1 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/auropharma\/\">More Aurobindo Pharma news and dated analysis \u2192<\/a><\/p>\n<p><strong>Article by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-10-05\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-10-05\/\"}, \"headline\": \"Why Aurobindo Pharma Shares Slipped 0.11% Today Amid Sector Weakness | 5 October 2026\", \"description\": \"Aurobindo Pharma shares edged down 0.11% to \u20b91,674.90, tracking broader Nifty Pharma sector weakness. Read the latest regulatory updates and stock analysis.\", \"datePublished\": \"2026-10-05T02:27:40Z\", \"dateModified\": \"2026-10-05T14:43:53.354897+00:00\", \"author\": {\"@type\": \"Organization\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"WittyTrades\", \"url\": \"https:\/\/www.wittytrades.com\/\"}, \"inLanguage\": \"en-IN\", \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/auropharma-company-news-2026-10-05.jpg\"]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aurobindo Pharma shares edged down 0.11% to \u20b91,674.90, tracking broader Nifty Pharma sector weakness. Read the latest regulatory updates and stock analysis.<\/p>\n","protected":false},"author":1,"featured_media":2708,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Why Aurobindo Pharma Shares Slipped 0.11% Today Amid Sector Weakness | 5 October 2026","_witty_meta_description":"Aurobindo Pharma shares edged down 0.11% to \u20b91,674.90, tracking broader Nifty Pharma sector weakness. Read the latest regulatory updates and stock analysis.","_witty_primary_phrase":"Aurobindo Pharma share price 2026-10-05","_witty_reason_label":"Sector-linked consolidation and low-volume drift","_witty_reason_confidence":"low","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[89],"class_list":["post-2176","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-auropharma"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/2176","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=2176"}],"version-history":[{"count":4,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/2176\/revisions"}],"predecessor-version":[{"id":2711,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/2176\/revisions\/2711"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/2708"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=2176"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=2176"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=2176"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}